Quote | Gain Therapeutics Inc. (NASDAQ:GANX)
Last: | $1.075 |
---|---|
Change Percent: | -4.02% |
Open: | $1.13 |
Close: | $1.12 |
High: | $1.13 |
Low: | $1.06 |
Volume: | 184,824 |
Last Trade Date Time: | 07/24/2024 03:00:00 am |
News | Gain Therapeutics Inc. (NASDAQ:GANX)
2024-07-22 07:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are not for everyone, let’s make that perfectly clear. It’s challenging to invest in a field in which companies – particularly startups – can go f...
GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August GT-02287 on Track To Initiate Clinical Trial in Parkinson’s Disease Patients in Q4 2024 BETHESDA, Md., July 09, 2024 (GLOBE NEWSW...
Message Board Posts | Gain Therapeutics Inc. (NASDAQ:GANX)
Subject | By | Source | When |
---|---|---|---|
,,,,,,,REVERSAL OF FORTUNE!!! OUCH | THEMASTERS_SON | investorshub | 04/12/2022 7:22:34 PM |
Zoom presentation with Gain Therapeutics (Nasdaq: $GANX) this | RoadShowPartner | investorshub | 09/20/2021 9:18:07 PM |
Gain Therapeutics to Present at the Oppenheimer Fall | ProfitScout | investorshub | 09/17/2021 2:11:00 PM |
$GANX today announced that Eric Richman, Chief Executive | StockHighAlert- | investorshub | 09/17/2021 12:37:42 PM |
Nice green start here $GANX | StockHighAlert- | investorshub | 09/16/2021 1:59:43 PM |
News, Short Squeeze, Breakout and More Instantly...
Gain Therapeutics Inc. Company Name:
GANX Stock Symbol:
NASDAQ Market:
Gain Therapeutics Inc. Website:
GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August GT-02287 on Track To Initiate Clinical Trial in Parkinson’s Disease Patients in Q4 2024 BETHESDA, Md., July 09, 2024 (GLOBE NEWSW...
BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announc...